Heparin pharmacokinetics during hemodialysis

Area of Science:

• Pharmacokinetics
• Nephrology
• Internal Medicine

Background:

• Heparin is commonly used as an anticoagulant during hemodialysis.
• Understanding heparin's disposition is crucial for optimizing anticoagulation and minimizing bleeding risks in patients with chronic kidney disease.

Purpose of the Study:

• To investigate the pharmacokinetic profile of heparin in patients undergoing chronic hemodialysis.
• To determine key pharmacokinetic parameters including half-life, volume of distribution, and clearance.
• To assess the relationship between heparin distribution and patient blood/plasma volumes.

Main Methods:

• Studied heparin disposition in 21 chronic hemodialysis patients.
• Administered heparin via bolus injection (3,000-12,000 U).
• Analyzed heparin concentrations to determine pharmacokinetic parameters and elimination models.

Main Results:

• Demonstrated combined zero and first-order heparin elimination.
• Observed a 74% decline in heparin half-life over 3.5 hours during dialysis.
• Mean first-order parameters: half-life 117 min, volume of distribution (V) 68 ml/kg, clearance 28 ml/min.
• Heparin's volume of distribution significantly exceeded plasma volume, indicating distribution outside the plasma compartment.
• Blood volume approximated heparin's volume of distribution.

Conclusions:

• Heparin elimination during hemodialysis follows a combined zero and first-order model.
• Blood volume can serve as an approximation for heparin's volume of distribution in these patients.
• Significant interpatient variability in heparin pharmacokinetics suggests that individualized dosing strategies may be beneficial.